Overall, obesity-associated endocrine deregulation marked by alterations in adiponectin, leptin, insulin, IGF1 and estrogens contributes to increased risk of cancer progression and recurrence in obese breast cancer patients. The gene discussed is IGF1; the disease is obesity due to melanocortin 4 receptor deficiency.